Medication info

PeriPlus 2.5% Solution

Prescription medicationSolution
Ingredient · strength
Glucose Hydrate›68.85gCalcium Chloride Hydrate›0.507gMagnesium Chloride›0.14gSodium Chloride›8.43gSodium Bicarbonate›3.29gSodium Lactate 50%›5.26g
Manufacturer / importer
Boryung Pharmaceutical Co., Ltd.
Appearance
This medicine is a transparent peritoneal dialysis solution that is light yellow and contained within a plastic bag with two chambers, clear and colorless.
Packaging
2L/bag (Note: A solution:B solution = 725:1275)
Approval status
Active

MFDS item code 200401268 · Notified 2004.07.12

Summary

Main use
Peritoneal dialysis for renal failure, detoxification of drug poisoning, relief of discomfort caused by low-pH dialysate
Who uses it
Adults
Adult dosage
1. The attending physician should adjust the treatment regimen, number of exchanges, exchange volume, dialysis time, and treatment duration according to the patient's condition. 2. Use as a solution for dialysis treatment by intraperitoneal administration. 3. The dose varies according to body size, and the frequency of solution exchanges should be adjusted appropriately based on biochemical parameters and fluid balance. In general, adults receive 1.5~2.5L intraperitoneally per exchange, which is retained for 4~8 hours and then drained; this process is performed 3~5 times daily. 4. When a machine is used intermittently or continuously for peritoneal dialysis, it is preferable to use a bag with a volume greater than the machine's exchange volume. 5. The glucose concentration should be selected according to the patient's ultrafiltration needs and kept as low as possible.

Ingredients

Manufacturer
Boryung Pharmaceutical Co., Ltd.

Efficacy & effects

Peritoneal dialysis for renal failure, detoxification of drug poisoning, relief of discomfort caused by low-pH dialysate

  • Acute and chronic renal failure
  • drug overdose
  • discomfort due to low pH.
View approved original text

This medicine is used as a peritoneal dialysis solution for patients with acute and chronic renal failure, providing a detoxification effect against potential drug overdoses that may occur during the dialysis process. Additionally, it helps improve discomfort caused by low pH when using lactate-only dialysis solutions. This medication aims to enhance safety and efficacy during the treatment of renal failure and to reduce patients' discomfort.

Dosage and Administration

Adult dosage

1. The attending physician should adjust the treatment regimen, number of exchanges, exchange volume, dialysis time, and treatment duration according to the patient's condition. 2. Use as a solution for dialysis treatment by intraperitoneal administration. 3. The dose varies according to body size, and the frequency of solution exchanges should be adjusted appropriately based on biochemical parameters and fluid balance. In general, adults receive 1.5~2.5L intraperitoneally per exchange, which is retained for 4~8 hours and then drained; this process is performed 3~5 times daily. 4. When a machine is used intermittently or continuously for peritoneal dialysis, it is preferable to use a bag with a volume greater than the machine's exchange volume. 5. The glucose concentration should be selected according to the patient's ultrafiltration needs and kept as low as possible.

Precautions

This medication is used in peritoneal dialysis treatment and abrupt discontinuation can pose a risk to life. Caution is required as certain patients should not use this drug, such as those with diaphragmatic perforation, severe abdominal burns, severe peritoneal adhesion, or at risk of bleeding. Patients with lactic acidosis, severe electrolyte abnormalities, those who have recently undergone abdominal surgery, inflammatory bowel disease patients, patients with tumors or hernias in the abdomen, severe lung diseases, or septic patients need careful evaluation before use. Patients with inadequate protein intake or significant weight loss, or those who cannot follow treatment instructions from their physician, also require caution. When using this drug, patients taking digitalis preparations should frequently check serum potassium levels, and patients suspected of having glucose metabolism disorders should regularly test blood sugar. Other considerations include those with lumbar disorders, patients with ostomy use, diuretic users, severe ventilation disorders, obesity, steroid users, immunocompromised patients, antibiotic allergies, pregnant or nursing individuals, patients with peritonitis, and patients with hyperparathyroidism. While using this medication, adverse reactions such as abdominal pain, bleeding, peritonitis, inflammation, or catheter issues may occur. Gastrointestinal symptoms may include nausea, abdominal pain, diarrhea, constipation, hemorrhoids, vomiting, lack of appetite, abdominal bloating, bowel obstruction, hypokalemia, hyponatremia, hypocalcemia, hypophosphatemia, hyperlactatemia, hypomagnesemia, hypercholesterolemia, hypertriglyceridemia, metabolic acidosis, and others. There is a risk of infection or sepsis occurring during the peritoneal dialysis process, so aseptic handling in a clean environment is essential. Accurate confirmation of the dialysis solution's composition, careful observation of body weight and fluid status, and possible nutritional supplementation of proteins and vitamins may be necessary. Diabetics should frequently monitor their blood sugar and adjust insulin dosages. Early discontinuation of peritoneal dialysis can lead to fluid overload and uremia. This medication can affect the blood concentrations of other drugs during dialysis, necessitating dosage adjustments as needed, and caution is required when using with calcium or vitamin D-containing drugs to avoid hypercalcemia. The safety of this medication has not been established for pregnant or nursing women; it should only be used when the therapeutic benefits outweigh the risks. In children, the dosage of the dialysis solution should be adjusted according to weight and age, and in elderly patients, the risk of hernia should be considered. In case of overdose, dehydration, electrolyte abnormalities, and hyperglycemia may occur, requiring immediate medical attention. The peritoneal dialysis solution should only be used if the provided container has not been opened; the medication should not be used if the packaging is damaged or if the solution appears cloudy. It is intended for intraperitoneal dialysis only. Always check the state of the container before use, and the dialysis solution should be warmed to body temperature before administration. Any unused dialysis solution should be discarded, and when adding medications, it should be done aseptically and quickly.

Side effects

Abdominal pain, bleeding, peritonitis, abdominal pain, cloudy discharge, fever, inflammation around the abdominal catheter, redness, secretion, catheter damage, subcutaneous inflammation in case of drainage difficulties, nausea, diarrhea, constipation, hemorrhoids, vomiting, loss of appetite, abdominal distension, intestinal obstruction, hypokalemia, hyponatremia, hypocalcemia, hypophosphatemia, hyperlactatemia, hypomagnesemia, hypercholesterolemia, hypertriglyceridemia, metabolic acidosis, hypoalbuminemia, hyperglycemia, dyspnea due to diaphragm elevation, pulmonary edema, pleural effusion, secondary hyperparathyroidism, edema, amino acid loss, water-soluble vitamin loss, shoulder pain, muscle spasms, hernia, scrotal swelling, obesity, weakness, fainting, fatigue, headache, dizziness, tachycardia, hypertension, hypotension, sclerosing encapsulating peritonitis, sepsis

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a sealed container to prevent air or moisture ingress; do not freeze, and keep in a cool place below 25 degrees Celsius. This storage method will safely maintain the medication's efficacy.

Appearance and packaging

Appearance

This medicine is a transparent peritoneal dialysis solution that is light yellow and contained within a plastic bag with two chambers, clear and colorless.

Package unit

2L/bag (Note: A solution:B solution = 725:1275)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.